|
Stem cell origin of myelodysplastic syndromes
|
Dec 2013
|
Oncogene
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes in children: where are we today?
|
Jan 2012
|
Ochsner J
|
myelodysplastic syndromes (MDS)
|
|
Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
|
Jan 2012
|
Neoplasma
|
myelodysplastic syndromes (MDS)
|
|
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|
Aug 2020
|
Nature Medicine
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version
|
Mar 2019
|
National Cancer Institute
|
myelodysplastic syndromes (MDS)
|
|
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
|
Jan 2015
|
Nat Commun.
|
myelodysplastic syndromes (MDS)
|
|
Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells
|
Mar 2015
|
Nat Biotechnol
|
myelodysplastic syndromes (MDS)
|
|
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
|
Sep 2015
|
N Engl J Med
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|
Nov 2016
|
N Engl J Med
|
myelodysplastic syndromes (MDS)
|
|
A promising new treatment for refractory aplastic anemia
|
Jul 2012
|
N Engl J Med
|
aplastic anemia
|
